ChloroquineV1, Main, Exploration, bibRecord, 000331

The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells

Identifieur interne : 000331 ( Main/Exploration ); précédent : 000330; suivant : 000332

The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells

Auteurs : Junping Pan [République populaire de Chine] ; Chenglin Lu [République populaire de Chine] ; Wang Jun [République populaire de Chine] ; Yafu Wu [République populaire de Chine] ; Xiaolei Shi [République populaire de Chine] ; Yitao Ding [République populaire de Chine]

Source :

International Journal of Clinical and Experimental Pathology [ 1936-2625 ] ; 2019.

RBID : PMC:6949556

Abstract

Background: Sorafenib is one of the most commonly used systemic therapies for hepatocellular carcinoma (HCC), but the acquired resistance towards sorafenib found in HCC patients usually led to failure of treatment and poor prognosis. Therefore, there is an urgent need to study the molecular mechanism caused by the acquired resistance. Previous studies demonstrated that P62 plays an important role in tumor cell resistance towards systemic therapies including chemotherapy and targeted therapy. However, the role of P62 in acquired resistance to sorafenib in HCC has not been clearly investigated. Materials and methods: In this study we screened the most sensitive HCC cell lines towards sorafenib using CCK8. Then on this cell line, we analyzed the relationship between P62 expression level and the sensitivity towards sorafenib by western blot and CCK8. After knockdown and overexpression of P62 in HCC cells, cells were then treated with sorafenib. After that, we detect changes of sensitivity towards sorafenib. HCC samples were used to investigate the expression of P62 and their survival time. Results: Among four HCC cell lines in our lab, HepG2 cell line with the highest sensitivity to sorafenib was screened and selected. After treatment with sorafenib, the expression of P62 was significantly increased. In HCC cells, we found that significant up-regulation of P62 was correlated with the reduction of sorafenib sensitivity. In HCC samples, we found that the expression of P62 was associated with sorafenib resistance and a shorter survival time. Conclusion: The up-regulation of P62 could reduce the sensitivity of HCC towards sorafenib. Thus, P62 could be therapeutic target to overcome sorafenib acquired resistance in the future.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949556

PubMed: 31934090
PubMed Central: 6949556

Affiliations:

République populaire de Chine

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells</title>
<author><name sortKey="Pan, Junping" sort="Pan, Junping" uniqKey="Pan J" first="Junping" last="Pan">Junping Pan</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Hepatobiliary Surgery, The Drum Tower Clinical Medical College, Nanjing Medical University</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lu, Chenglin" sort="Lu, Chenglin" uniqKey="Lu C" first="Chenglin" last="Lu">Chenglin Lu</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jun, Wang" sort="Jun, Wang" uniqKey="Jun W" first="Wang" last="Jun">Wang Jun</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wu, Yafu" sort="Wu, Yafu" uniqKey="Wu Y" first="Yafu" last="Wu">Yafu Wu</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shi, Xiaolei" sort="Shi, Xiaolei" uniqKey="Shi X" first="Xiaolei" last="Shi">Xiaolei Shi</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ding, Yitao" sort="Ding, Yitao" uniqKey="Ding Y" first="Yitao" last="Ding">Yitao Ding</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Hepatobiliary Surgery, The Drum Tower Clinical Medical College, Nanjing Medical University</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">31934090</idno>
<idno type="pmc">6949556</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949556</idno>
<idno type="RBID">PMC:6949556</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000364</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000364</idno>
<idno type="wicri:Area/Pmc/Curation">000364</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000364</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000295</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000295</idno>
<idno type="wicri:Area/Ncbi/Merge">000E28</idno>
<idno type="wicri:Area/Ncbi/Curation">000E28</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E28</idno>
<idno type="wicri:Area/Main/Merge">000331</idno>
<idno type="wicri:Area/Main/Curation">000331</idno>
<idno type="wicri:Area/Main/Exploration">000331</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells</title>
<author><name sortKey="Pan, Junping" sort="Pan, Junping" uniqKey="Pan J" first="Junping" last="Pan">Junping Pan</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Hepatobiliary Surgery, The Drum Tower Clinical Medical College, Nanjing Medical University</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lu, Chenglin" sort="Lu, Chenglin" uniqKey="Lu C" first="Chenglin" last="Lu">Chenglin Lu</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jun, Wang" sort="Jun, Wang" uniqKey="Jun W" first="Wang" last="Jun">Wang Jun</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wu, Yafu" sort="Wu, Yafu" uniqKey="Wu Y" first="Yafu" last="Wu">Yafu Wu</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shi, Xiaolei" sort="Shi, Xiaolei" uniqKey="Shi X" first="Xiaolei" last="Shi">Xiaolei Shi</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ding, Yitao" sort="Ding, Yitao" uniqKey="Ding Y" first="Yitao" last="Ding">Yitao Ding</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Hepatobiliary Surgery, The Drum Tower Clinical Medical College, Nanjing Medical University</institution>
<addr-line>Nanjing, Jiangsu Province, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanjing, Jiangsu Province</wicri:regionArea>
<wicri:noRegion>Jiangsu Province</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">International Journal of Clinical and Experimental Pathology</title>
<idno type="eISSN">1936-2625</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Background: Sorafenib is one of the most commonly used systemic therapies for hepatocellular carcinoma (HCC), but the acquired resistance towards sorafenib found in HCC patients usually led to failure of treatment and poor prognosis. Therefore, there is an urgent need to study the molecular mechanism caused by the acquired resistance. Previous studies demonstrated that P62 plays an important role in tumor cell resistance towards systemic therapies including chemotherapy and targeted therapy. However, the role of P62 in acquired resistance to sorafenib in HCC has not been clearly investigated. Materials and methods: In this study we screened the most sensitive HCC cell lines towards sorafenib using CCK8. Then on this cell line, we analyzed the relationship between P62 expression level and the sensitivity towards sorafenib by western blot and CCK8. After knockdown and overexpression of P62 in HCC cells, cells were then treated with sorafenib. After that, we detect changes of sensitivity towards sorafenib. HCC samples were used to investigate the expression of P62 and their survival time. Results: Among four HCC cell lines in our lab, HepG2 cell line with the highest sensitivity to sorafenib was screened and selected. After treatment with sorafenib, the expression of P62 was significantly increased. In HCC cells, we found that significant up-regulation of P62 was correlated with the reduction of sorafenib sensitivity. In HCC samples, we found that the expression of P62 was associated with sorafenib resistance and a shorter survival time. Conclusion: The up-regulation of P62 could reduce the sensitivity of HCC towards sorafenib. Thus, P62 could be therapeutic target to overcome sorafenib acquired resistance in the future.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Pan, Junping" sort="Pan, Junping" uniqKey="Pan J" first="Junping" last="Pan">Junping Pan</name>
</noRegion>
<name sortKey="Ding, Yitao" sort="Ding, Yitao" uniqKey="Ding Y" first="Yitao" last="Ding">Yitao Ding</name>
<name sortKey="Jun, Wang" sort="Jun, Wang" uniqKey="Jun W" first="Wang" last="Jun">Wang Jun</name>
<name sortKey="Lu, Chenglin" sort="Lu, Chenglin" uniqKey="Lu C" first="Chenglin" last="Lu">Chenglin Lu</name>
<name sortKey="Shi, Xiaolei" sort="Shi, Xiaolei" uniqKey="Shi X" first="Xiaolei" last="Shi">Xiaolei Shi</name>
<name sortKey="Wu, Yafu" sort="Wu, Yafu" uniqKey="Wu Y" first="Yafu" last="Wu">Yafu Wu</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000331 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000331 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:6949556
   |texte=   The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31934090" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells

The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.